Literature DB >> 1066988

Experimental autoimmune myasthenia gravis and myasthenia gravis: biochemical and immunochemical aspects.

J M Lindstrom, V A Lennon, M E Seybold, S Whittingham.   

Abstract

Stucture of acetylcholine receptor protein (AChR) purified from Electrophorus electricus (eel) by affinity chromatography is described. AChR is detected in extracts from human muscle, rat muscle, and rat thymus. Rats immunized with eel AChR develop humoral antibodies, a small fraction of which recognize AChR from rat muscle. Rats immunized with AChR exhibit myasthenia, but those immunized with denatured AChR do not. Immunoglobulin fraction of antisera to eel AChR can block the activity of AChR in electroplaques. Sera from patients with myasthenia gravis contain antibodies to AChR from human muscle detectabe at an average value 300-fold the background level in sera from nonmyasthenics. Relationship of thymoma and disease intensity to antibody titer is examined. The chronic phase of EAMG appears a good model of MG, since in both cases similar concentrations of 7-S immunoglobulin against determinants on muscle AChR other than the toxin binding site are found. Assay of anti-AChR antibody in sera from MG patients using AChR from rat muscle gives titers 10%-15% of those obtained using AChR from human muscle, and using AChR from eel gives negligible titers. The assay method described for assaying antibodies against AChR from human muscle is suggested as a diagnostic test for MG.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1066988     DOI: 10.1111/j.1749-6632.1976.tb47691.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  50 in total

1.  Myasthenia associated with D-penicillamine therapy in rheumatoid arthritis.

Authors:  R C Bucknall
Journal:  Proc R Soc Med       Date:  1977

2.  Specific immunotherapy of experimental myasthenia gravis by a novel mechanism.

Authors:  Jie Luo; Alexander Kuryatov; Jon M Lindstrom
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

3.  Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors.

Authors:  Jie Luo; Jon Lindstrom
Journal:  Autoimmunity       Date:  2011-10-21       Impact factor: 2.815

4.  Splenectomy in the treatment of severe forms of myasthenia.

Authors:  B M Gekht; M I Kuzin; O S Shkrob; P S Vetshev; I Kh Ippolitov; A G Sanadze; D I Shagal; Z Sh Khodzhaev
Journal:  Neurosci Behav Physiol       Date:  1991 Sep-Oct

5.  Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis.

Authors:  Pilar Martínez-Martínez; Mario Losen; Hans Duimel; Peter Frederik; Frank Spaans; Peter Molenaar; Angela Vincent; Marc H De Baets
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

6.  Effects of the rate of acetylcholine receptor synthesis on the severity of experimental autoimmune myasthenia gravis.

Authors:  M H De Baets; J Verschuuren; M R Daha; P J van Breda Vriesman
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

7.  Subpopulations of T lymphocytes in myasthenia gravis patients.

Authors:  M Piantelli; L Lauriola; A Carbone; A Evoli; P Tonali; P Musiani
Journal:  Clin Exp Immunol       Date:  1979-04       Impact factor: 4.330

8.  Myasthenogenicity of the main immunogenic region.

Authors:  Jon Lindstrom; Jie Luo
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

9.  Antibodies to polyadenylic acid in patients with myasthenia gravis.

Authors:  M Fischbach; J Lindstrom; N Talal
Journal:  Clin Exp Immunol       Date:  1981-01       Impact factor: 4.330

10.  Acetylcholinesterase activity and menstrual remissions in myasthenia gravis.

Authors:  N Vijayan; V K Vijayan; P M Dreyfus
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-11       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.